587 related articles for article (PubMed ID: 33949694)
21. The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using
Jiao J; Quan Z; Zhang J; Wen W; Qin J; Yang L; Meng P; Jing Y; Ma S; Wu P; Han D; Davis AA; Ren J; Yang X; Kang F; Zhang Q; Wang J; Qin W
Front Oncol; 2021; 11():658669. PubMed ID: 33937073
[TBL] [Abstract][Full Text] [Related]
22. External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
Meijer D; van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN
Eur Urol; 2021 Aug; 80(2):234-242. PubMed ID: 34024652
[TBL] [Abstract][Full Text] [Related]
23. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
24. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
25. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
26. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography.
Vis AN; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; Heymans MW; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes AM; Oprea-Lager DE; Coughlin GD; van Leeuwen PJ
Eur Urol Oncol; 2023 Dec; 6(6):553-563. PubMed ID: 37045707
[TBL] [Abstract][Full Text] [Related]
27. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD
J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
[TBL] [Abstract][Full Text] [Related]
28. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
29. Prediction nomogram for
Ceci F; Bianchi L; Borghesi M; Polverari G; Farolfi A; Briganti A; Schiavina R; Brunocilla E; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):136-146. PubMed ID: 31492993
[TBL] [Abstract][Full Text] [Related]
30. Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management.
Koerber SA; Stach G; Kratochwil C; Haefner MF; Rathke H; Herfarth K; Kopka K; Holland-Letz T; Choyke PL; Haberkorn U; Debus J; Giesel FL
J Nucl Med; 2020 Jan; 61(1):46-50. PubMed ID: 31302638
[TBL] [Abstract][Full Text] [Related]
31.
Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
[TBL] [Abstract][Full Text] [Related]
32. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C
Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958
[TBL] [Abstract][Full Text] [Related]
33. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
34. One-Stop-Shop Whole-Body
Thalgott M; Düwel C; Rauscher I; Heck MM; Haller B; Gafita A; Gschwend JE; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2018 Dec; 59(12):1850-1856. PubMed ID: 29794224
[TBL] [Abstract][Full Text] [Related]
35. Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and
Wang Y; Tang Y; Gao X; Gan Y; Hu S; Chen MF; Cai Y
Prostate; 2022 Nov; 82(15):1415-1421. PubMed ID: 35860907
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract][Full Text] [Related]
37. Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?
Rogasch JM; Cash H; Zschaeck S; Elezkurtaj S; Brenner W; Hamm B; Makowski M; Amthauer H; Furth C; Baur ADJ
Prostate; 2018 Jul; ():. PubMed ID: 29978529
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic performance of
Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
[TBL] [Abstract][Full Text] [Related]
39. Comparison of
Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic accuracy of
Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
